HUP0301830A2 - Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes - Google Patents
Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetesInfo
- Publication number
- HUP0301830A2 HUP0301830A2 HU0301830A HUP0301830A HUP0301830A2 HU P0301830 A2 HUP0301830 A2 HU P0301830A2 HU 0301830 A HU0301830 A HU 0301830A HU P0301830 A HUP0301830 A HU P0301830A HU P0301830 A2 HUP0301830 A2 HU P0301830A2
- Authority
- HU
- Hungary
- Prior art keywords
- inhibitors
- diabetes
- treatment
- combination
- insulin
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 5
- 229940125708 antidiabetic agent Drugs 0.000 title abstract 2
- 239000003472 antidiabetic agent Substances 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 abstract 1
- 229940127438 Amylin Agonists Drugs 0.000 abstract 1
- 229940123208 Biguanide Drugs 0.000 abstract 1
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 abstract 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 abstract 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 abstract 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 229940122199 Insulin secretagogue Drugs 0.000 abstract 1
- 229940122355 Insulin sensitizer Drugs 0.000 abstract 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 150000004283 biguanides Chemical class 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- -1 insulin sensitizers Chemical class 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Abstract
A találmány tárgya gyógyszerkészítmény, amely legalább egygyógyászatilag hatékony mennyiségű FBP-áz inhibitort és legalább egygyógyászatilag hatékony mennyiségű antidiabetikus szert tartalmaz. Azalkalmazott antidiabetikumok az inzulin szekretagóg vegyületek,inzulin vagy inzulin-analógok, inzulin-érzékenyítők, biguanidok, alfa-glukozidáz inhibitorok, glikogén-foszforiláz inhibitorok, glukóz-6-foszfatáz inhibitorok; glukagon antagonisták, amilin-agoniták észsírsav-oxidáció gátlók közül kerülnek kiválasztásra. A találmánytovábbá ezen vegyületek kombinációjának alkalmazására vonatkozikcukorbetegség kezelésére szolgáló gyógyszerkészítmények előállítására. ÓThe subject of the invention is a pharmaceutical preparation that contains at least a single-therapeutically effective amount of an FBP-ase inhibitor and at least a single-therapeutically effective amount of an antidiabetic agent. Antidiabetics used are insulin secretagogue compounds, insulin or insulin analogs, insulin sensitizers, biguanides, alpha-glucosidase inhibitors, glycogen phosphorylase inhibitors, glucose-6-phosphatase inhibitors; glucagon antagonists, amylin agonists are selected from fatty acid oxidation inhibitors. The invention further relates to the use of a combination of these compounds for the production of pharmaceutical compositions for the treatment of diabetes. HE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21653100P | 2000-07-06 | 2000-07-06 | |
| PCT/US2001/021557 WO2002003978A2 (en) | 2000-07-06 | 2001-07-05 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0301830A2 true HUP0301830A2 (en) | 2003-11-28 |
| HUP0301830A3 HUP0301830A3 (en) | 2007-10-29 |
Family
ID=22807416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0301830A HUP0301830A3 (en) | 2000-07-06 | 2001-07-05 | Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1372660A2 (en) |
| JP (1) | JP2004508297A (en) |
| KR (1) | KR100854851B1 (en) |
| CN (2) | CN100396283C (en) |
| AU (2) | AU7327101A (en) |
| BR (1) | BR0112212A (en) |
| CA (1) | CA2412142A1 (en) |
| CZ (1) | CZ20035A3 (en) |
| HU (1) | HUP0301830A3 (en) |
| IL (2) | IL153513A0 (en) |
| MX (1) | MXPA02012713A (en) |
| NO (1) | NO20030034L (en) |
| NZ (1) | NZ523227A (en) |
| PL (1) | PL365779A1 (en) |
| RU (1) | RU2328308C2 (en) |
| SK (1) | SK62003A3 (en) |
| WO (1) | WO2002003978A2 (en) |
| ZA (1) | ZA200300044B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6452098A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| EP1112275B9 (en) | 1998-09-09 | 2004-03-10 | Metabasis Therapeutics, Inc. | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
| CZ20023018A3 (en) | 2000-03-08 | 2003-01-15 | Metabasis Therapeutics, Inc. | Novel fructose-1,6-bisphosphatase inhibitors containing aryl group |
| EP2050460A1 (en) | 2001-09-24 | 2009-04-22 | Imperial Innovations Limited | PYY and agonists thereof for modification of feeding behaviour |
| JP4733922B2 (en) | 2002-01-10 | 2011-07-27 | インペリアル・イノベ−ションズ・リミテッド | Correction of eating behavior |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| CA2551611C (en) | 2003-12-26 | 2013-06-25 | Kyowa Hakko Kogyo Co., Ltd. | Thiazole derivatives for treating or preventing parkinson's disease |
| JP2008510018A (en) * | 2004-08-18 | 2008-04-03 | メタバシス・セラピューティクス・インコーポレイテッド | Novel thiazole inhibitor of fructose-1,6-bisphosphatase |
| CN101119748A (en) * | 2004-12-13 | 2008-02-06 | 第一三共株式会社 | Pharmaceutical composition for treatment of diabetes |
| TW200738245A (en) * | 2005-08-22 | 2007-10-16 | Sankyo Co | Pharmaceutical composition containing FBPase inhibitor |
| WO2007129522A1 (en) * | 2006-04-10 | 2007-11-15 | Daiichi Sankyo Company, Limited | Preparation produced by dry process |
| EP2394647A1 (en) | 2006-11-02 | 2011-12-14 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways |
| TWI428346B (en) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| CN103665043B (en) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | A kind of tenofovir prodrug and its application in medicine |
| UY35065A (en) * | 2012-10-08 | 2014-05-30 | Lg Life Sciences Ltd | COMBINED DRUG THAT INCLUDES GEMIGLIPTINE AND METFORMIN AND METHOD FOR PREPARATION |
| CN104788350A (en) * | 2014-01-22 | 2015-07-22 | 天津大学 | Method for acquiring medicinally-advantageous crystal form of tolbutamide through rapid cooling and crystallization |
| CN106831437B (en) * | 2016-02-03 | 2019-06-21 | 华中师范大学 | Ester type compound and its preparation method and application containing nitroethenyl group |
| CN114907285B (en) * | 2021-02-10 | 2023-09-22 | 华中师范大学 | Acylated saccharin compound, preparation method and application thereof, and hypoglycemic drug |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL93164A0 (en) * | 1989-01-24 | 1990-11-05 | Gensia Pharma | Purine nucleosides and their medical use |
| WO1998039342A1 (en) * | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| AU6452098A (en) * | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| JP2001515482A (en) * | 1997-03-07 | 2001-09-18 | メタバシス・セラピューティクス・インコーポレイテッド | Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase |
| AU3087099A (en) * | 1998-03-16 | 1999-10-11 | Ontogen Corporation | Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase) |
| EP1112275B9 (en) * | 1998-09-09 | 2004-03-10 | Metabasis Therapeutics, Inc. | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
| PT1143955E (en) * | 1998-12-24 | 2005-11-30 | Metabasis Therapeutics Inc | COMBINATION OF FBPASE INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES |
| ES2436610T3 (en) * | 2000-01-21 | 2014-01-03 | Novartis Ag | Combinations containing dipeptidylpeptidase-IV inhibitors and antidiabetic agents |
| GB0015627D0 (en) * | 2000-06-26 | 2000-08-16 | Rademacher Group Limited | Phosphoglycan messengers and their medical uses |
-
2001
- 2001-07-05 EP EP01952530A patent/EP1372660A2/en not_active Withdrawn
- 2001-07-05 BR BR0112212-6A patent/BR0112212A/en not_active IP Right Cessation
- 2001-07-05 CN CNB018149243A patent/CN100396283C/en not_active Expired - Fee Related
- 2001-07-05 AU AU7327101A patent/AU7327101A/en active Pending
- 2001-07-05 CN CNA200810098112XA patent/CN101301294A/en active Pending
- 2001-07-05 CA CA002412142A patent/CA2412142A1/en not_active Abandoned
- 2001-07-05 MX MXPA02012713A patent/MXPA02012713A/en not_active Application Discontinuation
- 2001-07-05 JP JP2002508433A patent/JP2004508297A/en active Pending
- 2001-07-05 CZ CZ20035A patent/CZ20035A3/en unknown
- 2001-07-05 NZ NZ523227A patent/NZ523227A/en not_active IP Right Cessation
- 2001-07-05 HU HU0301830A patent/HUP0301830A3/en unknown
- 2001-07-05 RU RU2003103436/15A patent/RU2328308C2/en not_active IP Right Cessation
- 2001-07-05 AU AU2001273271A patent/AU2001273271B2/en not_active Ceased
- 2001-07-05 IL IL15351301A patent/IL153513A0/en unknown
- 2001-07-05 KR KR1020037000126A patent/KR100854851B1/en active IP Right Grant
- 2001-07-05 PL PL01365779A patent/PL365779A1/en unknown
- 2001-07-05 WO PCT/US2001/021557 patent/WO2002003978A2/en active IP Right Grant
- 2001-07-05 SK SK6-2003A patent/SK62003A3/en unknown
-
2002
- 2002-12-18 IL IL153513A patent/IL153513A/en not_active IP Right Cessation
-
2003
- 2003-01-02 ZA ZA200300044A patent/ZA200300044B/en unknown
- 2003-01-03 NO NO20030034A patent/NO20030034L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002003978A2 (en) | 2002-01-17 |
| CA2412142A1 (en) | 2002-01-17 |
| JP2004508297A (en) | 2004-03-18 |
| ZA200300044B (en) | 2004-05-06 |
| KR100854851B1 (en) | 2008-08-27 |
| CN1599612A (en) | 2005-03-23 |
| CZ20035A3 (en) | 2003-05-14 |
| NZ523227A (en) | 2005-04-29 |
| MXPA02012713A (en) | 2004-09-10 |
| NO20030034D0 (en) | 2003-01-03 |
| RU2328308C2 (en) | 2008-07-10 |
| WO2002003978A3 (en) | 2003-10-16 |
| SK62003A3 (en) | 2003-09-11 |
| AU2001273271B2 (en) | 2006-01-05 |
| NO20030034L (en) | 2003-03-05 |
| AU7327101A (en) | 2002-01-21 |
| PL365779A1 (en) | 2005-01-10 |
| BR0112212A (en) | 2003-12-30 |
| IL153513A0 (en) | 2003-07-06 |
| KR20030031952A (en) | 2003-04-23 |
| IL153513A (en) | 2014-07-31 |
| EP1372660A2 (en) | 2004-01-02 |
| HUP0301830A3 (en) | 2007-10-29 |
| CN101301294A (en) | 2008-11-12 |
| CN100396283C (en) | 2008-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0301830A2 (en) | Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes | |
| HUP0301194A2 (en) | Pharmaceutical compositions containing combinations of depeptidyl peptidase iv inhibitors and other antidiabetic agents and their use for the treatment of diabete mellitus | |
| ATE286500T1 (en) | 1,2,3,4-TETRAHYDROISOCINOLINE DERIVATIVES | |
| SE0102764D0 (en) | Compounds | |
| HUP0400365A2 (en) | 3-fluoro-pyrrolidines as antidiabetic agents and pharmaceutical compositions containing the compounds | |
| MXPA02011425A (en) | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors. | |
| NO20051102L (en) | Sulfonylamino-acetic acid derivatives | |
| HUP0204136A2 (en) | Methods for pulmonary delivery of interleukin-2 | |
| CA2407100A1 (en) | 1-aroyl-piperidinyl benzamidines | |
| MXPA05010137A (en) | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists. | |
| HUP0103542A2 (en) | 4,4-biarylpiperidine derivatives with opioid receptor activity and pharmaceutical compositions containing them | |
| HUP0402403A2 (en) | Dipeptidyl peptidase iv (dp-iv) inhibitors anti-diabetic agents pharmaceutical compositions coutaining thereof and their use | |
| IL168836A (en) | Pyrimidine-sulfamides and their use as endothelin receptor antagonist | |
| UY27320A1 (en) | NEW PHARMACEUTICAL COMPOSITIONS | |
| NO20034230D0 (en) | 1,2,3,4-tetrahydroisoquinoline derivatives as urotensin II receptor antagonists | |
| TW200514772A (en) | Novel tetrahydropyridine derivatives | |
| ES2184310T3 (en) | SELF-EMULSIONING FORMULATION FOR LIPOFIL ACID COMPOUNDS | |
| WO2005030209A8 (en) | Pyridine derivatives and use thereof as urotensin ii antagonists | |
| DE60225143D1 (en) | SYNERGISTIC PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OR PROPHYLAXIS OF DIABETES | |
| MXPA04001252A (en) | Novel benzo-fused heterocycles as endothelin antagonisits. | |
| ES8506621A1 (en) | Benzenesulphonyl lactams, process for their preparation and their use as active ingredients in pharmaceutical compounds | |
| HK1090062A1 (en) | Colchicoside analogues | |
| WO2002008200A3 (en) | Arylethene-sulfonamides, their preparation and their use as endothelin antagonists | |
| FR2368959A1 (en) | COMPOSITIONS CONTAINING GUANIDINOALCANOIC ACID DERIVATIVES, USED AS A MEDICINAL PRODUCT | |
| DE69805860D1 (en) | WATER-SOLUBLE SIMILAR COMPOUNDS AND PRELIMINARY MEDICINE FROM PACLITAXEL |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |